• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 8, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Janus bases among The Scientist’s Top Innovations of 2019

Bioengineer by Bioengineer
December 5, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Invented at Carnegie Mellon, the bivalent nucleic acid recognition platform is being used to develop treatments for rare genetic diseases

IMAGE

Credit: Carnegie Mellon University


The Scientist Magazine has named Janus bases as one of its Top 10 Innovations of 2019. Carnegie Mellon University Chemistry Professor Danith Ly invented the molecules, and they are being used to create new treatments for genetic diseases and disorders.

Janus bases are used to make two-sided synthetic analogs to DNA and RNA. The molecules can recognize and bind to DNA and RNA under normal physiological conditions, making them a promising platform for treating a wide range of genetic conditions including neurological diseases and muscular dystrophies.

Janus bases are being developed by NeuBase Therapeutics as a novel molecular platform for RNA-targeting drugs that silence or alter the expression of genes for the treatment of rare genetic diseases. NeuBase was founded and is led by CEO Dietrich Stephan, an alumnus of Carnegie Mellon’s Department of Biological Sciences. Ly serves as the company’s chief scientific officer.

Ly, who directs Carnegie Mellon’s Biomolecular Design and Discovery Institute, is a leading expert in creating peptide nucleic acids (PNAs). PNAs contain the same base pairs as DNA and RNA, but have a synthetic backbone. To further this technology, Ly created Janus bases, a set of bivalent nucleic acid recognition elements that can bind to any possible combination found in the genetic code. As a result, PNAs made with Janus bases can enter the double helix of DNA and RNA, search for detrimental sequences and bind to each side of the two strands and prevent a gene from malfunctioning.

Neubase uses PNAs with Janus bases to target and bind to mutant RNA and silence harmful genes by preventing translation or altering splicing of the genetic material. As a result, harmful proteins that cause disease are no longer produced.

###

Ly’s early work on Janus bases was made possible through a gift from the DSF Charitable Foundation to Carnegie Mellon’s Center for Nucleic Acids Science & Technology.

In its annual list of Top 10 Innovations, The Scientist identifies the latest and greatest tools, technologies and techniques in the life sciences. The innovations included on the list are selected by expert panels of independent judges. The Scientist is a publication for life-science professionals that is dedicated to covering a wide range of biological fields.

Media Contact
Jocelyn Duffy
[email protected]
412-268-9982

Original Source

https://www.cmu.edu/mcs/news-events/2019/1202_janus-bases-top-innovation.html

Tags: BiochemistryBiologyBiotechnologyChemistry/Physics/Materials SciencesGene TherapyGenesGeneticsMedicine/HealthneurobiologyPharmaceutical Sciences
Share13Tweet8Share2ShareShareShare2

Related Posts

New Phase II Trial Targets Advanced Follicular Lymphoma

New Phase II Trial Targets Advanced Follicular Lymphoma

August 8, 2025
Scientists Develop “Evolution Engine” to Accelerate Protein Reprogramming

Scientists Develop “Evolution Engine” to Accelerate Protein Reprogramming

August 8, 2025

Autoantibodies Trigger Sensory Neuron Pain in Rats

August 8, 2025

New Clue: Odorant Protein Fibrils Cause Smell Loss

August 8, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    76 shares
    Share 30 Tweet 19
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    51 shares
    Share 20 Tweet 13
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Japan Unveils Its First Fully Domestically Developed Quantum Computer

New Phase II Trial Targets Advanced Follicular Lymphoma

Eco-Friendly ZIF-7 Carbon for Sensitive Rhodamine B Detection

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.